Equity Overview
Price & Market Data
Price: $0.298
Daily Change: +$0.0866 / 29.10%
Range: $0.192 - $0.30
Market Cap: $4,839,316
Volume: 17,716
Performance Metrics
1 Week: -30.42%
1 Month: -38.49%
3 Months: -42.88%
6 Months: -65.08%
1 Year: -63.08%
YTD: -31.46%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. It has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., Merck &Co., Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Mercer Island, Washington.